Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial

Jaeheon Jeong, Byoung Chul Cho, Joo Hyuk Sohn, Hye Jin Choi, Se Hyun Kim, Young Joo Lee, Min Kyu Jung, Sang Joon Shin, Moo Suk Park, Se Kyu Kim, Joon Chang, Joo Hang Kim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Belotecan is a topoisomerase I inhibitor. This phase II trial was conducted to evaluate the efficacy and toxicity of belotecan in relapsing small-cell lung cancer (SCLC) patients after irinotecan failure. Patients and methods: SCLC patients, who had relapsed at least 3 months after achieving objective response to irinotecan plus platinum chemotherapy, were eligible. Belotecan was administered at a dose of 0.5mg/m2/day for 5 consecutive days every 3 weeks. Results: Twenty-seven patients were enrolled in this study. Twenty-five patients were evaluated for response, and 27 patients were evaluated for toxicity and survival. The overall response rate was 22%. The median time to progression was 4.7 months (95% CI, 3.6-5.8 months), and the median overall survival was 13.1 months (95% CI, 10.4-15.8 months). The most frequent grade 3/4 toxicities were neutropenia (93%) and thrombocytopenia (48%). There was one treatment-related death due to pneumonia. Conclusion: Belotecan showed modest activity and manageable toxicities in relapsing SCLC patients in this study which was conducted in Asia. But further study in Caucasian patients is needed.

Original languageEnglish
Pages (from-to)77-81
Number of pages5
JournalLung Cancer
Volume70
Issue number1
DOIs
Publication statusPublished - 2010 Oct 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial'. Together they form a unique fingerprint.

  • Cite this

    Jeong, J., Cho, B. C., Sohn, J. H., Choi, H. J., Kim, S. H., Lee, Y. J., Jung, M. K., Shin, S. J., Park, M. S., Kim, S. K., Chang, J., & Kim, J. H. (2010). Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial. Lung Cancer, 70(1), 77-81. https://doi.org/10.1016/j.lungcan.2010.01.006